Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258669 | 0.93 | AKT1 (0.33) | PTGDRFFAR4KITPTGIR | |
| SCHEMBL21258940 | 0.91 | PTGIR (0.35) | TSHRPTGIR | |
| SCHEMBL21258691 | 0.90 | CKS1B (0.33) | — | |
| SCHEMBL21258676 | 0.90 | PTGIR (0.38) | PTGDRPTGIR | |
| SCHEMBL21258828 | 0.89 | PTGIR (0.37) | PTGDRPTGIR | |
| SCHEMBL21258705 | 0.88 | PTGIR (0.35) | FFAR4PTGIR | |
| SCHEMBL21258877 | 0.88 | PTGIR (0.37) | PTGDRPTGIR | |
| SCHEMBL21258966 | 0.84 | PTGIR (0.40) | PTGDRPTGIR | |
| SCHEMBL21258899 | 0.84 | PTGIR (0.39) | PTGDRFFAR4TSHRPTGIR | |
| SCHEMBL21258991 | 0.84 | PTGIR (0.43) | PTGDRPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | CHINESE PLA GENERAL HOSPITAL (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | PTGDR 9/4885FFAR4 177/4885KIT 1080/4885 |
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | PTGIR, CYP11B2, PDE8A | PTGDR 29/4885FFAR4 567/4885KIT 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.